Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CASH FLOWS

v2.4.0.6
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Cash flows from operating activities:      
Net loss $ (2,710) $ (3,501) $ (3,842)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:      
Depreciation and amortization 355 363 522
(Gain) loss on the sales of fixed assets (28) 0 104
Impairment charge 0 0 74
Share-based compensation expense 631 192 0
Sales discounts and provision for bad debts (18) (33) (133)
Inventory valuation provision (115) (728) 633
Changes in operating assets and liabilities:      
Accounts receivable 1,620 (1,189) 2,485
Inventory (891) 451 963
Prepaid expenses and other assets (864) (68) 390
Accounts payable 396 (219) (109)
Accrued advertising and other allowances (565) 1,384 (597)
Other operating assets and liabilities, net 81 (201) (45)
Net cash provided by (used in) operating activities (2,108) (3,549) 445
Cash flows from investing activities:      
Capital expenditures (300) (153) (208)
Acquisition of product license 0 (1,000) 0
Proceeds from the sale of fixed assets 166 0 480
Net cash flows provided by (used in) investing activities (134) (1,153) 272
Cash flows from financing activities:      
Proceeds from the exercise of stock options 0 133 127
Purchase of treasury stock (449) 0 0
Net cash provided by (used in) financing activities (449) 133 127
Net increase (decrease) in cash and cash equivalents (2,691) (4,569) 844
Cash and cash equivalents at beginning of year 8,232 12,801 11,957
Cash and cash equivalents at end of year 5,541 8,232 12,801
Supplemental disclosures of cash flow information:      
Income taxes paid 0 34 43
Common stock issued to Phosphagenics Limited pursuant to a product license agreement 0 2,577 0
Common stock issued, in lieu of cash, as payment of accrued compensation $ 294 $ 0 $ 0